Health Economics Outcomes Research Category Procurement Intelligence Report 2026-2030

The global HEOR services market is valued at approximately $1.65 billion in 2025, with projections pointing to roughly $5-6 billion by 2034-2035 based on various industry analyses. The market encompasses a range of services including real-world evidence generation, health economic modeling, market access strategy, outcomes measurement, and advisory consulting. The core function of HEOR is to bridge clinical research with real-world healthcare decision-making, ensuring that new treatments demonstrate not only safety and efficacy but also economic and societal value.

• •Service categories include real-world data analysis, health economic modeling, market access solutions, and outcomes consulting
• •Primary clients are pharmaceutical and biotechnology companies seeking reimbursement and formulary placement for new therapies
• •Payer organizations and health technology assessment bodies also rely heavily on HEOR evidence to inform coverage decisions

The market's strong expansion is fueled by the rising cost of drug development, which has made value demonstration a critical step in bringing new therapies to market. Healthcare systems globally are demanding stronger evidence on cost-effectiveness before reimbursing treatments, while regulatory agencies increasingly require real-world evidence to support product approvals and label expansions. The proliferation of specialty drugs and cell and gene therapies, which command premium prices, has intensified the need for robust economic and outcomes justification. Additional tailwinds include growing adoption of value-based contracting arrangements and the integration of artificial intelligence to process larger real-world datasets more efficiently.

• •Escalating pharmaceutical R&D spending, with average drug development costs approaching $2-3 billion per approved molecule
• •Expansion of Health Technology Assessment frameworks across Europe, Asia-Pacific, and increasingly North America
• •Growing demand for real-world evidence to support regulatory submissions, payer negotiations, and clinical guidelines

The market is commonly segmented by service type, real-world evidence and data analytics, health economic modeling and outcomes research, and market access consulting, as well as by end-user, with biopharmaceutical companies representing the largest client base. Geographically, North America accounts for the largest share of the HEOR market, followed by Europe and the emerging Asia-Pacific region. North American demand is particularly driven by the complex U.S. payer landscape, growing real-world evidence requirements from FDA, and the expansion of outcomes-based contracting between manufacturers and payers.

• •Biotechnology and pharmaceutical companies remain the dominant end-user segment across all regions
• •Contract research organizations and specialized consulting firms provide the majority of HEOR services
• •Asia-Pacific is expected to show the fastest relative growth as health technology assessment capabilities mature in countries including China, India, and South Korea

What are the recent trends and outlook?

The long-term outlook for the HEOR market remains strongly positive, with the convergence of value-based healthcare, digital health, and precision medicine reshaping evidence requirements across the industry. Emerging trends include greater reliance on patient-reported outcomes and patient preference data to inform treatment value assessments, the growth of decentralized clinical trials generating real-world evidence in parallel with traditional clinical development, and the increasing standardization of methods for economic evaluation across health technology assessment agencies. As healthcare systems continue to face budget constraints and seek to maximize the value of their spending, the strategic importance of HEOR in product development and market access is likely to deepen considerably over the coming decade.

• •Integration of artificial intelligence and machine learning into HEOR workflows is accelerating analysis of large-scale real-world datasets
• •Patient-centric outcomes measurement and patient preference studies are gaining prominence in health economic evaluations
• •Decentralized and hybrid clinical trial models are blurring the traditional lines between clinical research and real-world evidence generation